Solid Biosciences Inc. Stock News

Solid Biosciences Inc. (SLDB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Analysts predict that Solid Biosciences Inc. (NASDAQ:SLDB) will report sales of $3.48 million for the current quarter, according to Zacks. Three analysts have made estimates for Solid Biosciences’ earnings, with the highest sales estimate coming in at $3.50 million and the lowest estimate coming in at $3.43 million. The company is scheduled to issue its […]

Brokerages expect that Solid Biosciences Inc. (NASDAQ:SLDB) will announce earnings per share (EPS) of ($0.19) for the current quarter, according to Zacks. Three analysts have made estimates for Solid Biosciences earnings, with estimates ranging from ($0.21) to ($0.17). Solid Biosciences reported earnings of ($0.31) per share in the same quarter last year, which indicates a []

Equities research analysts expect Solid Biosciences Inc. (NASDAQ:SLDB) to announce earnings of ($0.19) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Solid Biosciences earnings, with estimates ranging from ($0.21) to ($0.17). Solid Biosciences posted earnings per share of ($0.31) in the same quarter last year, which [] The post Zacks: Brokerages Anticipate Solid Biosciences Inc. (NASDAQ:SLDB) to Post -$0.19 Earnings Per Share appeared first on ETF Daily News .

Solid Biosciences Inc. (NASDAQ:SLDB) price on Friday, December 10, fall -4.95% below its previous days close as a downside momentum from buyers pushed the stocks value to $1.73. A look at the stocks price movement, the level at last check in todays session was $1.82, moving within a range at $1.81 and $1.94. The beta Things To Consider When Buying Solid Biosciences Inc. (NASDAQ:SLDB) Shares Read More »

NEW YORK , Dec. 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ISIG, RLX, SLDB, LUV, and INFI. Full story available on Benzinga.com

Solid Biosciences Inc. (NASDAQ:SLDB) has been given an average recommendation of Hold by the seven ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The average 12-month []

Wall Street brokerages expect that Solid Biosciences Inc. (NASDAQ:SLDB) will announce sales of $3.48 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Solid Biosciences earnings, with estimates ranging from $3.43 million to $3.50 million. The business is expected to announce its next earnings results on Monday, []

During the recent session, Solid Biosciences Inc. (NASDAQ:SLDB)s traded shares were 0.8 million, with the beta value of the company hitting 0.88. At the last check today, the stocks price was $1.87, reflecting an intraday loss of -8.78% or -$0.18. The 52-week high for the SLDB share is $11.58, that puts it down -519.25 from What To Expect As Solid Biosciences Inc. (NASDAQ: SLDB) Delivers An -46.75% Loss In 6 Months Read More »

REGENXBIO (RGNX) is developing a gene therapy candidate, RGX-202, for treating DMD, which is currently in the pre-clinical stage. An IND application is expected by the end of 2021.

Analysts predict that Solid Biosciences Inc. (NASDAQ:SLDB) will report sales of $3.48 million for the current quarter, according to Zacks. Three analysts have made estimates for Solid Biosciences earnings, with the highest sales estimate coming in at $3.50 million and the lowest estimate coming in at $3.43 million. The company is scheduled to issue its []

Solid Biosciences Inc. (NASDAQ:SLDB) price on Thursday, November 18, fall -3.81% below its previous days close as a downside momentum from buyers pushed the stocks value to $2.02. A look at the stocks price movement, the close in the last trading session was $2.10, moving within a range at $1.98 and $2.12. The beta value Solid Biosciences Inc.s (NASDAQ:SLDB) Stock Price Plummets -73.35% This Year: A Look At Likely Future Paths Read More »

Renaissance Technologies LLC acquired a new position in shares of Solid Biosciences Inc. (NASDAQ:SLDB) during the second quarter, HoldingsChannel.com reports. The firm acquired 384,785 shares of the companys stock, valued at approximately $1,408,000. A number of other institutional investors also recently made changes to their positions in SLDB. Geode Capital Management LLC lifted its position []

Vanguard Group Inc. decreased its stake in shares of Solid Biosciences Inc. (NASDAQ:SLDB) by 2.6% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,762,778 shares of the companys stock after selling 73,049 shares during the quarter. Vanguard Group Inc.s holdings in Solid Biosciences []

Solid Biosciences Inc. (NASDAQ:SLDB) price closed higher on Monday, November 15, jumping 0.93% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy